Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.

Abstract

OBJECTIVE:

The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention-deficit/hyperactivity disorder (ADHD).

METHODS:

In a double blind placebo-controlled clinical trial, the efficacy of 8 mg/day of reboxetine (twice daily) was compared with placebo in 40 adults diagnosed with ADHD during 6 weeks. The measures were Conners' Adult ADHD Rating Scale-Self-Report, Screening Version (CAARS-S, SV), Hamilton Anxiety and Depression Rating Scales, Clinical Global Impression - Severity Scale (CGI-S), and Global Assessment of Functioning Scale (GAF).

RESULTS:

There was a main effect of time and significant time X treatment (reboxetine vs. placebo) interaction on CAARS subscales and CGI scores which decreased along the study (p < 0.01). There was also a main effect of time and time X treatment interaction on GAF score which increased at the end point of the study (p < 0.01). In terms of Hamilton Anxiety and Depression Rating Scales there was just a main effect of time on Hamilton Depression Scale (p < 0.01). Irritability, anxiety, sleep disturbance, and dry mouth were the common side effects of reboxetine.

CONCLUSION:

Reboxetine could be used and tolerated as an effective treatment for adults with ADHD.

• Authors: Forough Riahi, Mehdi Tehrani-Doost, Zahra Shahrivar, Javad Alaghband-Rad
• Journal: Human psychopharmacology (Hum Psychopharmacol) Vol. 25 Issue 7-8 Pg. 570-6 (Nov 2010) ISSN: 1099-1077 [Electronic] England
• PMID: 21312292 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 John Wiley & Sons, Ltd.

Chemical References

• Antidepressive Agents
• Morpholines
• Placebos
• Reboxetine

Topics

• Adult
• Antidepressive Agents (adverse effects, therapeutic use)
• Attention Deficit Disorder with Hyperactivity (drug therapy)
• Double-Blind Method
• Female
• Humans
• Male
• Morpholines (adverse effects, therapeutic use)
• Placebos
• Psychiatric Status Rating Scales
• Reboxetine
• Treatment Outcome